The cell and gene therapy (CGT) industry is on track to hit a record number of regulatory approvals this year—and the boom could have big implications for commercial real estate.
Life sciences employment is riding high and the marketplace is increasingly demanding accelerated innovation. But real estate development happens at a slower pace, leading to a supply shortfall that has left many enterprises engaged in large-scale research, development and production in the lurch.
According to Global Data, 582 CGT clinical trials commenced last year as regulatory approvals of new gene therapy and gene-modified cell therapy products gathered steam, and the first quarter of this year has seen an additional 138 clinical trials.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
